Work

A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)

Year: 2020

Type: article

Abstract: We conducted a multi-site, randomized controlled trial examining the strategy of switching from olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate metabolic risk factors for cardiovascular disease.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/54z2-xq08

Authors: Rosenheck, Robert A., Perkins, Diana O., Hamer, Robert H., Stroup, T. Scott, McEvoy, Joseph P., LaVange, Lisa M., Nussbaum, Abraham M., Lieberman, Jeffrey A., Swartz, Marvin S., Ring, Kimberly D.

Language: English

Topic: Schizophrenia research and treatment

Subfield: Psychiatry and Mental health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: Foundation for the National Institutes of Health, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Teva Pharmaceutical Industries, CeNeRx, Sunovion, Les Laboratories Pierre Fabre, Mylan, H. Lundbeck A/S, National Institutes of Health, Allergan, National Institute of Mental Health

Award: G975365284

OpenAlex ID: W4300828617

FWCI:

Cites:

Cited by:

Related to: 10